Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Thursday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

NASDAQ:EGRX opened at $3.95 on Thursday. Eagle Pharmaceuticals has a 52-week low of $3.21 and a 52-week high of $15.91. The stock has a fifty day moving average of $4.50 and a 200 day moving average of $4.66. The firm has a market capitalization of $51.30 million, a price-to-earnings ratio of 3.35 and a beta of 0.53.

Institutional Trading of Eagle Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in EGRX. Headlands Technologies LLC raised its position in Eagle Pharmaceuticals by 75.7% during the 1st quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 2,861 shares during the last quarter. Mackenzie Financial Corp purchased a new position in shares of Eagle Pharmaceuticals during the second quarter valued at approximately $60,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eagle Pharmaceuticals during the second quarter valued at approximately $65,000. Fidelis Capital Partners LLC purchased a new stake in Eagle Pharmaceuticals in the second quarter worth $71,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in Eagle Pharmaceuticals in the second quarter worth $76,000. 85.36% of the stock is owned by institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.